Document Detail

Significance of antinuclear antibody testing in unexplained second and third trimester fetal deaths.
MedLine Citation:
PMID:  9584815     Owner:  NLM     Status:  MEDLINE    
The purpose of this study was to determine if a group of patients with unexplained second or third trimester fetal demise have an increased prevalence of antinuclear antibodies (ANA) when compared to controls. During a 5-year period from January 1989 through December 1993, the records of all fetal deaths > or = 500 g or > or = 20 weeks of gestation that occurred at our institution were reviewed. In these women the ANA titers were checked at the discretion of the physician. The proportion of positive ANA tests in the group of women with explained fetal deaths was compared to that in women with unexplained fetal deaths. These results were then compared to a control group of healthy gravidas presenting to labor and delivery in the third trimester. During this time period, 848 fetal deaths were recorded. Our study population consisted of 286 patients who had an unexplained second or third trimester fetal demise with a record of having an ANA drawn. Of the 376 explained fetal deaths, 190 had an ANA assayed. The control group included 299 healthy third trimester gravidas. In the group of patients with unexplained fetal death, 11.5% (33/286) had a positive ANA, whereas 16% (31/190) of ANA tests were positive in cases of explained fetal death (P = 0.17). In the control group, 14% (43/299) had a positive ANA. There were three distinct immunofluorescence patterns: nucleolar, speckled, and homogeneous. The first two were seen more often in the control group, whereas the latter was seen more frequently in those patients with fetal death (P = 0.10). The incidence of a significant circulating ANA titer was similar in patients and controls. Moreover, there was no significant association between circulating antinuclear antibody titers and fetal outcome. More patients with a fetal death had a homogeneous nuclear fluorescence pattern when compared to controls; however, this finding was not statistically significant. Therefore, we do not recommend routine testing for ANA in women with unexplained second or third trimester fetal death.
M H Incerpi; E H Banks; S N Goodwein; R Samadi; T M Goodwin
Related Documents :
9854825 - The death of king charles xii--the forensic verdict.
12753075 - Glutamate transport alteration triggers differentiation-state selective oxidative death...
12814505 - The role of methadone in drug-related deaths in the west of scotland.
11214385 - The 'redefinition of death' debate: western concepts and western bioethics.
12666465 - Parental acceptance, postpartum depression, and maternal sensitivity: mediating and mod...
11665315 - Should all twins be delivered by caesarean section? a preliminary report.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  The Journal of maternal-fetal medicine     Volume:  7     ISSN:  1057-0802     ISO Abbreviation:  J Matern Fetal Med     Publication Date:    1998 Mar-Apr
Date Detail:
Created Date:  1998-06-17     Completed Date:  1998-06-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9211288     Medline TA:  J Matern Fetal Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  61-4     Citation Subset:  IM    
Department of Obstetrics and Gynecology, Los Angeles County/University of Southern California Medical Center, 90033, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Antinuclear / blood*,  immunology
Cohort Studies
Fetal Death / blood,  etiology*,  immunology
Fluorescent Antibody Technique, Indirect
Medical Records
Pregnancy Trimester, Second
Pregnancy Trimester, Third
Prospective Studies
Retrospective Studies
Reg. No./Substance:
0/Antibodies, Antinuclear

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Aseptics and aesthetics of chlorine bleach: can its use in laundering be safely abandoned?
Next Document:  Applicability of the third-generation, thyroid-stimulating hormone assay in pregnancy.